Updates from Industry
Announcing the addition of Axumin® (fluciclovine (18F)) to the EAU guidelines for imaging in patients with biochemical recurrence in Prostate Cancer.
The aim of the EAU Guidelines is to assist practicing clinicians in making informed decisions in a given circumstance; taking the highest quality scientific data, their patient’s personal circumstances, values and preferences into account. This is great news for BED as it’s a clear recognition of the clinical value of Axumin in Europe.
Please find attached the latest communication regarding Curium's Brexit Contingency plans.
Due to the recent approval of an extension until 31st October, Curium will revert back to Road freighting each day as of Sunday 14th April.
Customer Services in Portsmouth will work directly with customers to check their deliveries for next week and ensure they have the correct activity arriving on the correct day.